Drug Profile
CYT 001
Alternative Names: CYT-001Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator NEC Corporation; Yamaguchi University
- Developer CYTLIMIC; Yamaguchi University
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver cancer
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Late-stage disease, Adjuvant therapy) in Japan (SC, Injection)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Adjuvant therapy) in Japan
- 29 Sep 2021 CYTLIMIC has patent protection on heat shock protein 70 peptides in European Union